|
US7883704B2
(en)
|
1999-03-25 |
2011-02-08 |
Abbott Gmbh & Co. Kg |
Methods for inhibiting the activity of the P40 subunit of human IL-12
|
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
|
JP2003530092A
(ja)
*
|
2000-03-17 |
2003-10-14 |
ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト |
ヒトＦＡＰ−α−特異抗体
|
|
PE20021080A1
(es)
*
|
2001-04-12 |
2003-02-12 |
Boehringer Ingelheim Int |
Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
|
|
WO2004001004A2
(en)
*
|
2002-06-21 |
2003-12-31 |
Johns Hopkins University School Of Medicine |
Membrane associated tumor endothelium markers
|
|
US8530627B2
(en)
|
2002-08-14 |
2013-09-10 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8187593B2
(en)
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
EP1534335B9
(en)
|
2002-08-14 |
2016-01-13 |
Macrogenics, Inc. |
Fcgammariib-specific antibodies and methods of use thereof
|
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8044180B2
(en)
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8946387B2
(en)
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8193318B2
(en)
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US7384744B2
(en)
|
2002-11-29 |
2008-06-10 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
|
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス，インコーポレーテッド |
変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
JP2006517802A
(ja)
*
|
2003-02-14 |
2006-08-03 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
外来性分子の一過性の発現もしくは安定な発現のための発現カセットおよび発現ベクター
|
|
WO2005110474A2
(en)
|
2004-05-10 |
2005-11-24 |
Macrogenics, Inc. |
HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
EP1810035A4
(en)
|
2004-11-10 |
2010-03-17 |
Macrogenics Inc |
GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
|
|
HUE029465T2
(en)
|
2005-08-10 |
2017-02-28 |
Macrogenics Inc |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
US10155816B2
(en)
*
|
2005-11-28 |
2018-12-18 |
Genmab A/S |
Recombinant monovalent antibodies and methods for production thereof
|
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
|
US7786270B2
(en)
|
2006-05-26 |
2010-08-31 |
Macrogenics, Inc. |
Humanized FcγRIIB-specific antibodies and methods of use thereof
|
|
WO2008002933A2
(en)
|
2006-06-26 |
2008-01-03 |
Macrogenics, Inc. |
Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
|
|
HUE030269T2
(en)
|
2006-06-26 |
2017-04-28 |
Macrogenics Inc |
FC RIIB-specific antibodies and methods for their use
|
|
WO2008140603A2
(en)
|
2006-12-08 |
2008-11-20 |
Macrogenics, Inc. |
METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
|
|
CN104524567A
(zh)
|
2007-01-16 |
2015-04-22 |
阿布维公司 |
用于治疗银屑病的方法
|
|
CA2681752A1
(en)
|
2007-03-29 |
2008-10-09 |
Abbott Laboratories |
Crystalline anti-human 1l-12 antibodies
|
|
AU2009258063B2
(en)
|
2007-06-21 |
2014-09-25 |
Macrogenics, Inc. |
BCR-complex-specific antibodies and methods of using same
|
|
ES2473623T3
(es)
*
|
2007-08-20 |
2014-07-07 |
Glaxo Group Limited |
Procedimiento de producción
|
|
ES2527649T3
(es)
*
|
2007-12-10 |
2015-01-28 |
F. Hoffmann-La Roche Ag |
Panel de marcadores para el cáncer colorrectal
|
|
EP2071337A1
(en)
*
|
2007-12-10 |
2009-06-17 |
F.Hoffmann-La Roche Ag |
Seprase as a marker for cancer
|
|
MX2010004671A
(es)
*
|
2007-12-10 |
2010-05-27 |
Hoffmann La Roche |
Seprasa como marcador para cancer.
|
|
EP2274333A4
(en)
|
2008-03-18 |
2011-06-15 |
Abbott Lab |
PROCESS FOR TREATING PSORIASIS
|
|
CN107325182A
(zh)
|
2008-04-02 |
2017-11-07 |
宏观基因有限公司 |
HER2/neu‑特异性抗体和其使用方法
|
|
KR20120112384A
(ko)
|
2009-09-14 |
2012-10-11 |
애보트 게엠베하 운트 콤파니 카게 |
건선을 치료하는 방법
|
|
WO2011044368A1
(en)
|
2009-10-07 |
2011-04-14 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
|
JP5998060B2
(ja)
|
2010-03-04 |
2016-09-28 |
マクロジェニクス，インコーポレーテッド |
Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
HUE036077T2
(hu)
*
|
2010-08-13 |
2018-06-28 |
Roche Glycart Ag |
Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások
|
|
PT2614082T
(pt)
|
2010-09-09 |
2018-12-03 |
Pfizer |
Moléculas de ligação a 4-1bb
|
|
HUE029139T2
(hu)
|
2011-02-10 |
2017-02-28 |
Roche Glycart Ag |
Mutáns interleukin-2 polipeptidek
|
|
PL2859017T3
(pl)
|
2012-06-08 |
2019-07-31 |
Sutro Biopharma, Inc. |
Przeciwciała zawierające swoiste dla miejsca, niewystępujące naturalnie reszty aminokwasowe, sposoby ich wytwarzania i sposoby ich zastosowania
|
|
WO2014004639A1
(en)
|
2012-06-26 |
2014-01-03 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
|
CN103267852B
(zh)
*
|
2013-05-15 |
2015-03-25 |
中国医学科学院北京协和医院 |
成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
|
|
ES2865473T3
(es)
|
2013-07-10 |
2021-10-15 |
Sutro Biopharma Inc |
Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
|
|
GB201402006D0
(en)
|
2014-02-06 |
2014-03-26 |
Oncomatryx Biopharma S L |
Antibody-drug conjugates and immunotoxins
|
|
LT3653644T
(lt)
*
|
2014-03-26 |
2024-01-25 |
Julius-Maximilians-Universität Würzburg |
Monokloniniai antikūnai prieš augimo ir diferenciacijos faktorių 15 (gdf- 15), ir jų panaudojimas taikant vėžio kacheksijos ir vėžio gydymą
|
|
CN105646710B
(zh)
*
|
2014-11-17 |
2020-08-25 |
四川科伦博泰生物医药股份有限公司 |
一种全人源化抗vegfr-2单克隆抗体及其制备方法
|
|
PE20240096A1
(es)
|
2015-10-02 |
2024-01-18 |
Hoffmann La Roche |
Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
|
|
SG11201806419RA
(en)
*
|
2016-01-27 |
2018-08-30 |
Sutro Biopharma Inc |
Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
|
|
TWI781098B
(zh)
|
2016-04-15 |
2022-10-21 |
美商宏觀基因股份有限公司 |
新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
|
|
RU2021127872A
(ru)
|
2016-06-30 |
2021-11-09 |
Онкорус, Инк. |
Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
|
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ |
新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
|
|
CN116474108A
(zh)
|
2016-12-14 |
2023-07-25 |
普渡研究基金会 |
成纤维细胞活化蛋白(fap)-靶向成像和治疗
|
|
US11865081B2
(en)
|
2017-12-29 |
2024-01-09 |
Virogin Biotech Canada Ltd. |
Oncolytic viral delivery of therapeutic polypeptides
|
|
CN110526979A
(zh)
*
|
2018-05-25 |
2019-12-03 |
深圳宾德生物技术有限公司 |
靶向fap的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
|
|
CN110526991A
(zh)
*
|
2018-05-25 |
2019-12-03 |
深圳宾德生物技术有限公司 |
靶向fap的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用
|
|
CN109053893B
(zh)
*
|
2018-08-15 |
2021-03-30 |
智享生物(苏州)有限公司 |
一种抗d-二聚体单克隆抗体及其制备方法
|
|
CN110882385B
(zh)
*
|
2018-09-07 |
2021-07-09 |
上海君实生物医药科技股份有限公司 |
抗pd-1抗体在治疗肿瘤中的用途
|
|
CN114853908B
(zh)
*
|
2019-05-16 |
2024-06-07 |
浙江道尔生物科技有限公司 |
一种治疗代谢疾病的融合蛋白
|
|
CN118406106A
(zh)
|
2019-07-08 |
2024-07-30 |
3B制药有限公司 |
包含成纤维细胞活化蛋白配体的化合物及其用途
|
|
EP3763726A1
(en)
|
2019-07-08 |
2021-01-13 |
3B Pharmaceuticals GmbH |
Compounds comprising a fibroblast activation protein ligand and use thereof
|
|
IL289673B2
(en)
|
2019-07-08 |
2026-04-01 |
3B Pharmaceuticals Gmbh |
Compounds comprising a protein ligand for fibroblast activation and their use
|
|
JP7628111B2
(ja)
|
2019-09-03 |
2025-02-07 |
バイオ － テラ ソリューションズ、リミテッド |
抗ｔｉｇｉｔ免疫阻害剤及び応用
|
|
CN113512116B
(zh)
*
|
2020-04-10 |
2022-09-20 |
苏州普乐康医药科技有限公司 |
一种抗igf-1r抗体及其应用
|
|
KR102363980B1
(ko)
*
|
2020-04-13 |
2022-02-15 |
전남대학교산학협력단 |
전이성 뇌종양의 진단 또는 예후 분석용 바이오마커 및 이를 이용한 진단방법
|
|
EP4143239A4
(en)
*
|
2020-04-30 |
2024-10-02 |
I-Mab Biopharma Co., Ltd. |
PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-CD47 ANTIBODIES
|
|
KR20230012559A
(ko)
|
2020-05-19 |
2023-01-26 |
베링거 인겔하임 인터내셔날 게엠베하 |
암 치료를 위한 결합 분자
|
|
WO2022007283A1
(zh)
*
|
2020-07-08 |
2022-01-13 |
深圳霁因生物医药转化研究院 |
用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质
|
|
EP4198051A4
(en)
*
|
2020-08-11 |
2024-05-01 |
Kanaph Therapeutics Inc. |
FUSION PROTEIN WITH IL-12 AND ANTI-FAP ANTIBODIES AND USE THEREOF
|
|
EP4050018A1
(en)
|
2021-01-07 |
2022-08-31 |
3B Pharmaceuticals GmbH |
Compounds comprising a fibroblast activation protein ligand and use thereof
|
|
KR20230129261A
(ko)
|
2021-01-07 |
2023-09-07 |
쓰리비 파마슈티컬스 게엠베하 |
섬유모세포 활성화 단백질 리간드를 포함하는 화합물및 그의 용도
|
|
WO2023031644A1
(en)
|
2021-08-31 |
2023-03-09 |
Full-Life Technologies Limited |
Anti-fibroblast activation protein (fap) single domain antibodies and uses thereof
|
|
US20250297032A1
(en)
*
|
2021-12-30 |
2025-09-25 |
Concept To Medicine Biotech Co., Ltd. |
Human antibodies against fap-alpha
|
|
EP4578877A1
(en)
|
2022-08-03 |
2025-07-02 |
Nanjing Leads Biolabs Co., Ltd. |
Antibody fusion protein targeting fap and tgf-beta, and use thereof
|
|
US20260053923A1
(en)
|
2022-10-07 |
2026-02-26 |
Genethon |
Immunotherapy of Skeletal Myopathies Using ANTI-FAP CAR-T Cells
|
|
CN116589566A
(zh)
*
|
2022-11-18 |
2023-08-15 |
昆明医科大学第一附属医院 |
一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用
|
|
WO2025152756A1
(zh)
*
|
2024-01-15 |
2025-07-24 |
迈威(上海)生物科技股份有限公司 |
重组抗fap抗体及其应用
|
|
CN118496382B
(zh)
*
|
2024-05-22 |
2025-01-07 |
山东第一医科大学附属省立医院(山东省立医院) |
一种靶向fap的嵌合抗原受体、car-t细胞及其在肝纤维化中的应用
|
|
CN118812715A
(zh)
*
|
2024-07-02 |
2024-10-22 |
国睿(广州)生物科技有限公司 |
一种靶向成纤维活化蛋白α的纳米抗体及其应用
|
|
CN119265201A
(zh)
*
|
2024-08-23 |
2025-01-07 |
中国人民解放军海军军医大学第一附属医院 |
编码基因、蛋白、表达il-15的nkg2dl-fap双靶点car-nk细胞及其构建方法和用途
|